actinium has been researched along with Disease Models, Animal in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Alidori, S; Almeida, BA; Bradbury, MS; Chen, F; Khanin, R; Korontsvit, T; Ma, K; McDevitt, MR; Mello, BP; Quinn, TP; Scheinberg, DA; Turker, MZ; Urbanska, AM; Wiesner, U; Wong, S; Zanzonico, PB | 1 |
| Aranda-Lara, L; Azorín-Vega, E; Nava-Cabrera, M; Oros-Pantoja, R | 1 |
| Almaguel, FG; Debinski, W; Herpai, DM; Mintz, A; Pandya, DN; Sattiraju, A; Solingapuram Sai, KK; Wadas, TJ; Xuan, A | 1 |
| Abdel-Atti, D; Carter, LM; Lewis, JS; Mandleywala, K; Membreno, R; Poty, S; Ragupathi, A; Scholz, WW; Zeglis, BM | 1 |
| Abbas Rizvi, SM; Allen, BJ; Fernandez, HR; Lutz-Mann, L; So, T; Song, EY | 1 |
| Blechert, B; Bruchertseifer, F; Essler, M; Gärtner, FC; Morgenstern, A; Neff, F; Seidl, C; Senekowitsch-Schmidtke, R | 1 |
6 other study(ies) available for actinium and Disease Models, Animal
| Article | Year |
|---|---|
A Genomic Profile of Local Immunity in the Melanoma Microenvironment Following Treatment with α Particle-Emitting Ultrasmall Silica Nanoparticles.
Topics: Actinium; Alpha Particles; Animals; Cell Line, Tumor; Computational Biology; Disease Models, Animal; Dose-Response Relationship, Radiation; Drug Carriers; Female; Gene Expression Regulation, Neoplastic; Humans; Immunity, Cellular; Male; Maximum Tolerated Dose; Melanoma, Experimental; Mice; Molecular Targeted Therapy; Nanoparticles; Radiopharmaceuticals; Receptor, Melanocortin, Type 1; RNA-Seq; Silicon Dioxide; Skin Neoplasms; Tissue Distribution; Tumor Microenvironment | 2020 |
Comparison between
Topics: Actinium; Animals; Bone Neoplasms; Cell Line, Tumor; Disease Models, Animal; Humans; Lutetium; Mice, Nude; Neoplasm Metastasis; Radioisotopes; Radiometry | 2021 |
IL13RA2 targeted alpha particle therapy against glioblastomas.
Topics: Actinium; Alpha Particles; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Copper Radioisotopes; Cysteamine; Disease Models, Animal; DNA Breaks, Double-Stranded; Gene Expression; Glioblastoma; Humans; Interleukin-13 Receptor alpha2 Subunit; Isotope Labeling; Male; Mice; Peptides; X-Ray Microtomography; Xenograft Model Antitumor Assays | 2017 |
Leveraging Bioorthogonal Click Chemistry to Improve
Topics: Actinium; Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Click Chemistry; Disease Models, Animal; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Humans; Immunoconjugates; Mice; Molecular Imaging; Pancreatic Neoplasms; Radiometry; Radiopharmaceuticals; Tissue Distribution; Translational Research, Biomedical; Treatment Outcome; Xenograft Model Antitumor Assays | 2019 |
Mutagenesis induced by targeted alpha therapy using 213Bi-cDTPA-9.2.27 in lacZ transgenic mice.
Topics: Actinium; Alpha Particles; Animals; Antibodies, Monoclonal; Brain; Disease Models, Animal; Humans; Immunoconjugates; Kidney; Lac Operon; Mice; Mice, Transgenic; Mutagenesis; Spleen; Tumor Suppressor Protein p53 | 2009 |
Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis.
Topics: Actinium; Animals; Bismuth; Cell Line, Tumor; Disease Models, Animal; Heterocyclic Compounds, 1-Ring; Humans; Isotope Labeling; Kidney; Mice; Organometallic Compounds; Pentetic Acid; Peptides; Peritoneal Neoplasms; Radioisotopes; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |